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Abstract In vitro virus is a molecular construct for in vitro
protein evolution, which requires some mechanism to link
phenotype to genotype. The first in vitro virus was realized by
bonding a nascent protein with its coding mRNA via puromycin
in in vitro translation. We report a new construct of in vitro DNA
virus. The virion was a covalent cDNA^protein fusion, and virion
formation did not require any modification of mRNA. Due to
intactness of mRNA, this type of in vitro DNA virus will take the
next step toward in vitro autonomous evolution, just like in vivo
viral evolution in a cellstat. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Evolutionary molecular engineering has been demonstrating
its e¡ectiveness in designing novel functional biopolymers.
The Darwinian selection process for proteins or peptides re-
quires some linking strategy between phenotype and genotype.
There are at least three such strategies both in the laboratory
and in nature [1]: virus-type, cell-type and external intelli-
gence-type. In virus-type linking strategy, the genotype mole-
cule (DNA or RNA) is bound to the phenotype molecule
(protein) directly just as in a simple bacteriophage particle
(virion). A phage display [2] and a cellstat [3] were developed
for the study of molecular evolution in the laboratory using
this strategy. An in vitro version of these methods has been
developed [4,5]. We called it in vitro virus [1,4] because it can
be regarded as the simplest virus with a single gene and a
single coat protein, and its ‘life cycle’ is turned over in vitro,
i.e. its ‘host’ is a test tube. The main reason is, of course, its
genotype^phenotype bonding strategy other than the com-
partmentalization strategy of a cellular organism [1]. By at-
taching puromycin to the 3P-end of an mRNA, a covalent
linkage between a nascent protein and its encoding mRNA
was made on a ribosome during in vitro translation. It dra-
matically increased the library diversity and the system £exi-
bility in comparison with the in vivo version. In fact, func-
tional proteins have been evolved starting from a random
library in this approach [6,7]. The original in vitro virus had
some problems. For example, it required a modi¢cation to the
mRNA template to attach puromycin-linker, and the template
could not tolerate harsh selective conditions because the geno-
type RNA molecule is fragile. Some in vitro selection systems
consisting of DNA^peptide fusion have been developed to
overcome the latter drawback. There are various types for
these DNA^peptide fusions [8^10]. But because these methods
still required modifying the evolving template, it was di⁄cult
to make an autonomously evolving molecular system.
We developed a new type of in vitro DNA virus, in which
the virion formation consisted of the following processes (Fig.
1): (1) hybridization of a DNA-primer with a puromycin-link-
er to an mRNA, (2) in vitro translation, and (3) reverse tran-
scription, which lead to cDNA^protein fusion. We developed
two constructs of the DNA-primer with a puromycin-linker;
L-linker-primer and T-linker-primer (Fig. 2A). Thus this in
vitro DNA virus is free from necessity of modi¢cations of
the evolving template.
2. Materials and methods
2.1. Synthesis of DNA-primer with puromycin-linker
The L-linker-primer and the DNA-primer moiety of the T-linker-
primer (5P-(GCCCCCCG)OMe(T-NH2)CCC-3P) were synthesized by
the use of a standard DNA synthetic method. The T-linker-primer
was synthesized in the ¢rst step as two separate parts by a DNA
synthesizer and each primary amine on the two parts was linked
together via bifunctional N-hydroxysuccinimide ester. 5P protection
of the puromycin-linker moiety of the T-linker-primer (5P-NH2-
(spacer18)4-(CC)OMe-puromycin-3P-controlled pore glass (CPG)) and
base protections of the DNA-primer moiety of T-linker-primer were
deprotected by standard protocols. Puromycin-CPG and phosphor-
amidites were purchased from Glen Research and used according to
the protocols recommended by the manufacturer. The puromycin-
linker moiety of the T-linker-primer (1 Wmol) was activated by Fluo-
roLink Cy3 reactive dye (1 mg) (Amersham Pharmacia) in dimethyl
sulfoxide (DMSO) for 30 min at 25‡C and washed with DMSO.
DNA-primer moiety (1 Wmol) was added and incubated in DMSO
for 3 h at 25‡C and washed with DMSO and TE bu¡er (10 mM
Tris^HCl, 1 mM EDTA, pH 8). Concentrated NH4OH was added
to remove the linker-primers from CPG and deprotection of bases was
performed for 8 h at 55‡C. The linker-primers were puri¢ed with a
reverse phase cartridge (Glen Research).
2.2. Construction of in vitro virus genome
Three constructs of in vitro virus genome, ‘His’(169 bp), ‘Flag’(127
bp), and ‘FLH’(177 bp)(Fig. 2B), were made. The plasmid pE-
THisKGFP was constructed by inserting green £uorescent protein
(GFP) gene of phGFPS65T (Clontech) into pETHisK vector [11].
DNA genomes were prepared by PCR with di¡erent primer sets in
two steps using the plasmid as an initial template.
Capped mRNAs were prepared using the DNA genomes and T7
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RNA polymerase transcription kit (RiboMAX-T7; Promega).
mRNAs (1 WM) were hybridized with each linker (3 WM) in an an-
nealing condition of 15 min/from 94 to 25‡C in 10 mM Tris^HCl,
1 mM MgCl2, 50 mM KCl (pH 8) and puri¢ed by a spin column
(S-200HR; Amersham Pharmacia).
2.3. Formation of in vitro DNA virion
The mRNAs were translated in wheat-germ extract (WGE; Prom-
ega) for 15 min at 25‡C in standard condition and for 30 min at 10‡C
in a high salt condition (¢nally, 50 mM MgCl2, 500 mM KCl). Trans-
lated products were desalted with the spin column. Reverse transcrip-
tion was performed using C. therm. Polymerase (Roche) for 30 min at
65‡C.
Virion formation was analyzed for ‘FLH’ genome. Virion forma-
tion procedure for this purpose was the same as described above
except that the virion was labeled with a £uorescent nucleotide (Flu-
oroLink Cy5-dCTP; Amersham Pharmacia) and a £uorescent amino
acid (FluoreTect Green in vitro translation labeling system; Prome-
ga), and WGE was purchased from Toyobo. The products were an-
alyzed using 6 M urea 10% SDS^Tricin PAGE [12] and visualized
using a £uorescence imager (Molecular Imager FX; Bio-Rad). Virion
formation analysis using PCR was performed through the same pro-
cedure described below as the selective enrichment analysis using
Ni^nitrilotriacetic acid (Ni^NTA) agarose gel, except that thiopropyl
Sepharose puri¢cation was omitted and PCR was performed normally
(25 cycles).
2.4. Selective enrichment analysis
A⁄nity columns of Ni^NTA agarose (QIAGEN; 200 Wl volume
(Vc)) and anti-Flag M2 antibody agarose (Sigma) were used. In vitro
DNA virions were puri¢ed with thiopropyl Sepharose (Sigma) as de-
scribed in [13]. Puri¢ed virion was diluted in a TBS bu¡er (50 mM
Tris^HCl, 150 mM NaCl, 0.1% Tween 20, pH 8.0) and incubated in
each a⁄nity column for 30 min at 25‡C. Ni^NTA agarose column
was washed with 25 Vc of a bu¡er (50 mM Tris^HCl, 1 M NaCl, 0.1%
Tween 20, 10 mM imidazole, pH 8.0) and eluted with 2.5 Vc of a
bu¡er (50 mM Tris^HCl, 0.1% Tween 20, 500 mM imidazole, pH 8.0).
Anti-Flag agarose was washed with 10 Vc of TBS and eluted with 2.5
Vc of a bu¡er (0.1 M glycine HCl, 0.1% Tween 20, pH 3.5). A com-
petitive PCR was performed (40 cycles) using KOD’ polymerase
(Toyobo). PCR products were analyzed by electrophoresis on 3%
agarose gel (MetaPhor agarose; FMC) using triethanolamine/Tricin
running bu¡er [14].
2.5. Puromycin incorporation analysis
Fluorescein-dC-puromycin was synthesized using a standard DNA
synthetic method and puri¢ed in the reverse phase HPLC. DNA-link-
er-primer/mRNA hybridization was performed through the same
procedure as described in Section 2.2. The translation reaction was
performed in WGE (Promega) according to the supplier’s recom-
mendation with 10 WM £uorescein-dC-puromycin. The translation
products were analyzed using 15% SDS^PAGE.
3. Results and discussion
3.1. Incorporation of puromycin at a double-stranded site
It is known that low concentration puromycin is incorpo-
rated into the C-terminus of the growing peptide at the
mRNA terminus [15] or at RNA^DNA junction [5]. We ex-
amined whether a hybridized double-stranded region on
mRNA could make the elongation reaction pause or not,
and puromycin could or could not be incorporated in this
condition. Full length mRNA for GFP was hybridized with
the anti-sense DNA-oligomer at about a third from the N-
terminus site of the coding region, and was translated with
£uorescence-labeled puromycin. The £uorescence-labeled pro-
tein of a third length was actually made (Fig. 3). This result
indicates that mRNA/DNA-primer hybridization region
makes peptide elongation reaction pause, and puromycin in-
corporation at the position follows. This process is applicable
to the puromycin-linker attachment process in the making of
in vitro virus. It has an advantage of rapidity and easiness
without any chemical or enzymatic modi¢cation of mRNA.
This method can attach the puromycin-linker at any position
of the mRNA target even if it contains the stop codon, where-
Fig. 1. ‘Life cycle’ of ‘in vitro virus’. In vitro virus ‘genome’(ds-
DNA) is transcribed to mRNA. The mRNA is hybridized to a
DNA-primer with a puromycin-linker, and translated. On a ribo-
some, puromycin is incorporated to the C-terminus of the nascent
protein. Reverse transcription starting from the DNA-primer gives
a stable cDNA^protein fusion (in vitro virus ‘virion’). The DNA
moiety of screened virions judging from the ‘¢tness’ of the protein
moiety is ampli¢ed.
Fig. 2. A: Two constructs of a DNA-primer with a puromycin-link-
er; L-linker-primer and T-linker-primer. S18: spacer18, a polyethyl-
ene glycol-like spacer. Puro: puromycin. OMe: 2P-O-Me-RNA.
B: Three constructs of in vitro virus genomes; ‘His’, ‘Flag’, and
‘FLH’. T7: T7 promoter. TMV: translational enhancer of TMV
5PUTR [24]. ATG: Initiation codon with good context [25]. His:
His-tag [26]. Flag: Flag epitope [27]. HMK: HMK site [11].
GFPN: N-terminus sequence in GFP gene with a mutation G4C.
Clump: GC-rich sequence for hybridization to the DNA-primer, a
GC clump.
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as the original ligation method can attach only at the termi-
nus.
The latter has another drawback associated with enzymatic
ligation by the use of a splint DNA and undesirable mRNA
terminal heterogeneity originated from T7 run-o¡ transcrip-
tion [16]. Recently, a linker attachment using photo-cross-
linking was reported [17]. Photo-cross-linking reaction, how-
ever, needs a long (15 min) UV irradiation. Whereas, mRNA/
DNA-primer hybridization seemed to be stable enough in this
experiment, because a full length protein was not observed in
lane D of Fig. 3. Therefore, there is no need to make a co-
valent bonding between mRNA and the puromycin-linker for
the translation process.
3.2. Virion formation of in vitro DNA virus
As a model system to examine the virion formation, we
used the genome ‘His’, which encoded GFP fragment with a
His-tag (Fig. 2B). The virion was made and screened through
a Ni^NTA-immobilized a⁄nity column. Bound virion mole-
cules were eluted and their moiety of DNA were ampli¢ed
and analyzed (Fig. 4). Two constructs with each type of the
linker-primers and a control without puromycin-linker were
examined.
During a single turnover in the ‘viral life cycle’, both puro-
mycin-linker-primers ampli¢ed the viral genomes (and also
the virions) well. The T-linker-primer showed about three-fold
higher ampli¢cation than the L-linker-primer. As the L-linker-
primer has a hybrid double-stranded region of low £exibility,
puromycin might not be able to approach a ribosome A-site
e⁄ciently. The T-linker-primer has a £exible spacer placed
near the 3P terminus of the DNA-primer. At the termination
of translation, the ribosome might be located just before the
3P end of the DNA-primer. So, puromycin is closer to the A-
site, and the local concentration of puromycin might be high-
er. A spacer placed near the 3P end of the DNA-primer did
not a¡ect the reverse transcription productivity (data not
shown). The T-linker-primer has oligonucleotide moiety of
2P-O-Me-RNA, which bound to RNA with much higher ther-
mostability than corresponding DNA [18]. Puromycin
(CC)OMe might interact stably to the ribosome A-site. 2P-O-
Me-RNA/mRNA is not cleaved by RNaseH activity, so
mRNA degradation might be lower. The oligonucleotide moi-
ety of the L-linker-primer was synthesized in 5P to 3P orienta-
tion using 5P-cyanoethyl phosphoramidites, but the L-linker-
primer was not with 2P-O-Me construction, because 5P-cya-
noethyl 2P-O-Me phosphoramidites were not commercially
available.
The electrophoretic pattern of virions (Fig. 5) showed a
successful virion formation. The cDNA and the peptide
were labeled with £uorescent dyes, Cy5 [19] and BODYPY-
FL [20], respectively. Detected £uorescent bands were in cor-
rect mobility. A lower mobility band of Cy5 emission and a
band of BODYPY-FL emission had the same mobility. It was
concluded that these bands corresponded to in vitro DNA
virus virion. The yield of cDNA^peptide linkage was about
10%.
3.3. Selective enrichment analysis
As a model system for demonstrating selection processes,
we used a mixture of ‘His’ and ‘Flag’ genomes (Fig. 2B) that
Fig. 3. Gel electrophoretic pattern showing incorporation of puro-
mycin. Various mRNAs were translated with 10 mM £uorescein-
dC-puromycin. Lane NT: control, without template. Lane F: Full
length GFP (261 aa) mRNA. Lane D: Full length GFP mRNA hy-
bridized with the DNA-oligomer at the region beginning at the
92nd aa site. Lane S: GFP N-terminus fragment (91 aa) mRNA.
The products were analyzed using 15% SDS^PAGE and visualized
using a £uorescence imager.
Fig. 4. Virion formation of in vitro DNA virus. Genome after single
turnover of viral life cycle with each of two linkers was electropho-
resed. Lane M: Fluorescent 100 base DNA ladder. Lane C: Con-
trol, with the DNA-primer without the puromycin-linker. Lane L:
With L-linker-primer. Lane T: With T-linker-primer. The products
were analyzed by electrophoresis on 3% agarose gel.
Fig. 5. Virion formation of in vitro DNA virus as revealed by dou-
ble £uorescence label. Lane D: Fluorescent DNA ladder. Lane C:
Virion in which cDNA moiety was labeled with £uorescent Cy5.
Lane B: Virion in which protein moiety was labeled with £uorescent
BODYPY-FL. Lane P: Protein molecular weight markers (precision
prestained protein standard; Bio-Rad). The imager with 635/670 nm
laser/¢lter set or 488/515 nm was used in lanes C and P, or, in lanes
B and D, respectively. The products were analyzed using 10% SDS^
Tricin PAGE with 6 M urea.
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contained a coding sequence of His-tag and Flag epitopes,
respectively. Starting from a 1:1 mixture of ‘His’ genome
and ‘Flag’ genome we made virions and screened them
through a Ni^NTA-immobilized a⁄nity column (for His-
tag) and through an anti-FLAG-immobilized a⁄nity column.
Bound virions were eluted and the DNA moiety was ampli¢ed
and analyzed by gel electrophoresis. ‘Flag’ genome was
slightly shorter than ‘His’ genome (Fig. 2B). PCR was per-
formed in a competitive mode and a £uorescence labeled
primer was used. Therefore the initial ratio of screened virions
could be analyzed using the imager (Fig. 6). A ‘His’ band was
enriched using a Ni^NTA agarose column and a ‘Flag’ band
was enriched using anti-Flag agarose column. The control
sample without screening was ampli¢ed, showing maintenance
of the original ratio of two genomes. The enrichment of about
two orders of magnitude was achieved per cycle. This value
will be large enough to select target protein from a library of
large diversity.
3.4. Conclusion
We demonstrated virion formation and selective enrichment
in a model system of in vitro DNA virus that consists of
cDNA^protein fusion without any mRNA modi¢cations.
In vitro DNA virus virion consists of a cDNA/mRNA hy-
brid double helix and a protein bound covalently to the
cDNA. This construct must be more stable than mRNA-pep-
tide fusion, and tolerate harsh and stringent selection condi-
tions, such as temperature stress-guided selection [21]. If high-
er stability will be required, the virion should be converted to
a double-stranded DNA.
This method will be able to be applied to the in vitro se-
lection not only for an arti¢cial library but also for a natural
mRNA library just as in the case of a linker attachment
method using photo-cross-linking [22].
As it is free from necessity of mRNA modi¢cations, in vitro
virus will take the next step toward autonomous evolution,
such as in vivo viral evolution in a cellstat. Combining the in
vitro DNA virus with an isothermal ampli¢cation method for
RNA/DNA such as 3SR (self-sustained sequence replication)
[23], a continuous ‘culture’ of the in vitro virus will be real-
ized. A £ow reactor for this viral life cycle reaction will be a
‘natural selection’-type evolution reactor [3] for a protein evo-
lution.
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